This study serves as an initial exploration of combining sPD-1 with a non-sPD-L1 biomarker across multiple cancers, demonstrating that incorporating sPD-1 has the potential to further enhance the diagnostic capabilities of the AR biomarker. Here, SPDL1 is linked to cancer.